Skip to main content

Publications in High Impact Factor Journals

Impact Factor of 10.0 or Higher

 

  1. Parks KR, MacCamy AJ, Trichka J, et al. Overcoming steric restrictions of VRC01 HIV-1 neutralizing antibodies through immunization. Cell Reports. 2019;29(10):3060-72.e7.
  2. Pinto D, Fenwick C, Caillat C, et al. Structural basis for broad HIV-1 neutralization by the MPER-specific human broadly neutralizing antibody LN01. Cell Host Microbe. 2019;26(5):623-37.e8.
  3. Li YJ, He YP, Butler W, et al. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Sci Transl Med. 2019;11(521).
  4. Boone PG, Rochelle LK, Ginzel JD, et al. A cancer rainbow mouse for visualizing the functional genomics of oncogenic clonal expansion. Nat Commun. 2019;10(1):5490.
  5. Pickar-Oliver A, Black JB, Lewis MM, et al. Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells. Nat Biotechnol. 2019;37(12):1493-1501.
  6. Cocce KJ, Jasper JS, Desautels TK, et al. The lineage determining factor GRHL2 collaborates with FOXA1 to establish a targetable pathway in endocrine therapy-resistant breast cancer. Cell Reports. 2019;29(4):889-903.e10.
  7. Ryser MD, Weaver DL, Zhao FM, et al. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. JNCI- Natl Cancer Inst. 2019;111(9):952-60.
  8. Neidich SD, Fong YY, Li SYS, et al. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. J Clin Invest. 2019;129(11):4838-49.
  9. Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med. 2019;381(16):1513-23.
  10. Loor G, Warnecke G, Villavicencio MA, et al. Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-arm, pivotal trial. Lancet Resp Med. 2019;7(11):975-84.
  11. Pantaleo G, Janes H, Karuna S, et al. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. Lancet HIV. 2019;6(11):E737-E49.
  12. Rouphael NG, Morgan C, Li SYS, Jensen R, Sanchez B, Karuna S, et al. DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. J Clin Invest. 2019;129(11):4769-85.
  13. Kwon JB, Gersbach CA. Jumping at the chance for precise DNA integration. Nat Biotechnol. 2019;37(9):1004-5.
  14. Gray GE, Huang Y, Grunenberg N, et al. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019;11(510).
  15. Gorman J, Mason RD, Nettey L, et al. Isolation and structure of an antibody that fully neutralizes isolate SIVmac239 reveals functional similarity of SIV and HIV glycan shields. Immunity. 2019;51(4):724-34.e4.
  16. Asokan A. CRISPR genome editing in stem cells turns to gold. Nat Mater. 2019;18(10):1038-9.
  17. Brouwer PJM, Antanasijevic A, Berndsen Z, et al. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nat Commun. 2019;10.
  18. Abdulhaqq SA, Martinez M, Kang G, et al. Repeated semen exposure decreases cervicovaginal SIVmac251 infection in rhesus macaques. Nat Commun. 2019;10(1):3753.
  19. Ding LN, Su Y, Fassl A, et al. Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. Nat Commun. 2019;10(1):4182.
  20. Fourati S, Ribeiro SP, Lopes F, et al. Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. Nat Commun. 2019;10.

  21. Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology a prospective blinded multicenter study. JAMA Oncol. 2019;5(2):204-12.
  22. Nelson CE, Wu YY, Gemberling MP, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019;25(3):427-+.
  23. Sui Y, Lewis GK, Wang YC, et al. Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. J Clin Invest. 2019;129(3):1314-28.
  24. Jones AT, Shen XY, Walter KL, et al. HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. Nat Commun. 2019;10.
  25. Turner MC, Behrens SL, Webster W, et al. Multidisciplinary approach to Clostridium difficile infection in adult surgical patients. J Am Coll Surg. 2019;228(4):570-80.
  26. Lawrence SA, McIntyre CA, Pulvirenti A, et al. Perioperative bundle to reduce surgical site infection after pancreaticoduodenectomy: A prospective cohort study. J Am Coll Surg. 2019;228(4):595-601.
  27. Kirkton RD, Santiago-Maysonet M, Lawson JH, et al. Bioengineered human acellular vessels recellularize and evolve into living blood vessels after human implantation. Sci Transl Med. 2019;11(485).
  28. Yau TM, Pagani FD, Mancini DM, et al. Intramyocardial injection of mesenchymal precursor cells and successful temporary weaning from left ventricular assist device support in patients with advanced heart failure a randomized clinical trial. JAMA-J Am Med Assoc. 2019;321(12):1176-86.
  29. Hu QS, Li CL, Wang SY, et al. LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition. Cell Res. 2019;29(4):286-304.
  30. Cecchini M, Rubin EH, Blumenthal GM, et al. Challenges with novel clinical trial designs: master protocols. Clin Cancer Res. 2019;25(7):2049-57.
  31. Priddy FH, Lewis DJM, Gelderblom HC, et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV. 2019;6(4):E230-E9.
  32. Wallis CJD, Butaney M, Satkunasivam R, et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers a systematic review and meta-analysis. JAMA Oncol. 2019;5(4):529-36.
  33. Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left ventricular assist device - final report. N Engl J Med. 2019;380(17):1618-27.
  34. Gerardo CJ, Vissoci JRN, Evans CS, Simel DL, Lavonas EJ. Does this patient have a severe snake envenomation? the rational clinical examination systematic review. JAMA Surg. 2019;154(4):346-54.
  35. Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019;35(4):588-+.
  36. DeRose JJ, Mancini DM, Chang HL, et al. Pacemaker implantation after mitral valve surgery with atrial fibrillation ablation. J Am Coll Cardiol. 2019;73(19):2427-35.
  37. Sliepen K, Han BW, Bontjer I, et al. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nat Commun. 2019;10.
  38. Han QF, Jones JA, Nicely NI, et al. Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nat Commun. 2019;10.
  39. Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395-405.
  40. Hu QS, Ye YQ, Chan LC, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019;20(7):835-+.
  41. Escolano A, Gristick HB, Abernathy ME, et al. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature. 2019;570(7762):468-+.
  42. Gleason TG, Reardon MJ, Popma JJ, et al. 5-year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients. J Am Coll Cardiol. 2018;72(22):2687-2696.
  43. Beltran H, Oromendia C, Danila DC, et al. A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res. 2019; 25(1):43-51.
  44. Inohara T, Manandhar P, Kosinski AS, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA. 2018;320(21):2231-2241.
  45. Mendoza P, Gruell H, Nogueira L, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561(7724):479-484.
  46. Barouch DH, Tomaka FL, Wegmann F, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018;392(10143):232-243.
  47. Bonsignori M, Scott E, Wiehe K, et al. Inference of the HIV-1 VRC01 antibody lineage unmutated common ancestor reveals alternative pathways to overcome a key glycan barrier. Immunity. 2018;49(6):1162-1174.e8.
  48. Sang LJ, Ju HQ, Liu GP, et al. LncRNA CamK-A regulates Ca2+-signaling-mediated tumor microenvironment remodeling. Mol Cell. 2018;72(1):71-83.e7.
  49. Ailawadi G, Lim DS, Mack MJ, et al. One-year outcomes after MitraClip for functional mitral regurgitation. Circulation. 2019;139(1):37-47.
  50. Gould RA, Aziz H, Woods CE, et al. ROBO4 variants predispose individuals to bicuspid aortic valve and thoracic aortic aneurysm. Nat Genet. 2019;51(1):42-50.
  51. Ackerman ME, Das J, Pittala S, et al. Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. Nat Med. 2018;24(10):1590-1598.
  52. Jayasekera J, Li Y, Schechter CB, et al. Simulation modeling of cancer clinical trials: application to omitting radiotherapy in low-risk breast cancer. J Natl Cancer Inst. 2018;110(12):1360-1369.
  53. Woroniecka K, Chongsathidkiet P, Rhodin K, et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res. 2018;24(17):4175-4186.
  54. Peacock WF, Baumann BM, Bruton D, Davis TE, Handy B, Jones CW, et al. Efficacy of High-Sensitivity Troponin T in Identifying Very-Low-Risk Patients With Possible Acute Coronary Syndrome. JAMA Cardiol. 2018;3(2):104-11.
  55. Bravata DM, Myers LJ, Arling G, Miech EJ, Damush T, Sico JJ, et al. Quality of Care for Veterans With Transient Ischemic Attack and Minor Stroke. Jama Neurology. 2018;75(4):419-27.
  56. Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018;24(4):408-416.
  57. Mehra MR, Goldstein DJ, Uriel N, Cleveland JC, Yuzefpolskaya M, Salerno C, et al. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med. 2018;378(15):1386-95.
  58. Gray BP, Kelly L, Ahrens DP, Barry AP, Kratschmer C, Levy M, et al. Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A. 2018;115(18):4761-6.
  59. Song HS, Giorgi EE, Ganusov VV, Cai FP, Athreya G, Yoon H, et al. Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun. 2018;9.
  60. Hayashi H, Hess DT, Zhang R, Sugi K, Gao HY, Tan BL, et al. S-Nitrosylation of beta-Arrestins Biases Receptor Signaling and Confers Ligand Independence. Mol Cell. 2018 May 3;70(3):473-487.e6.
  61. Rathkopf DE, Beer TM, Loriot Y, Higano CS, Armstrong AJ, Sternberg CN, et al. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer The PREVAIL Randomized Clinical Trial. JAMA Oncol. 2018;4(5):694-701.
  62. Slovin S, Clark W, Carles J, Krivoshik A, Park JW, Wang F, et al. Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure The UPWARD Study. JAMA Oncol. 2018;4(5):702-6.
  63. Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med. 2018;379(2):150-61.
  64. Gunaratne R, Kumar S, Frederiksen JW, Stayrook S, Lohrmann JL, Perry K, et al. Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. Nat Biotechnol. 2018 Aug;36(7):606-613.
  65. Nelson CS, Huffman T, Jenks JA, de la Rosa EC, Xie GH, Vandergrift N, et al. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl Acad Sci U S A. 2018;115(24):6267-72.
  66. Wang A, Gaca JG, Chu VH. Management Considerations in Infective Endocarditis A Review. JAMA. 2018 Jul 3;320(1):72-83.
  67. Wiehe K, Bradley T, Meyerhoff RR, Hart C, Williams WB, Easterhoff D, et al. Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Cell Host Microbe. 2018 Jun 13;23(6):759-765.e6.
  68. Zhao F, Xiao C, Evans KS, Theivanthiran T, DeVito N, Holtzhausen A, et al. Paracrine Wnt5a-beta-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization. Immunity. 2018 Jan 16;48(1):147-160.e7.
  69. Bekker LG, Moodie Z, Grunenberg N, Laher F, *Tomaras GD, Cohen KW, et al. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018;5(7):E366-E78.
  70. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018;379(2):111-21.
  71. Ferrari G. Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment. J Clin Invest. 2018;128(6):2189-91.
  72. Ryser MD, Min BH, Siegmund KD, Shibata D. Spatial mutation patterns as markers of early colorectal tumor cell mobility. Proc Natl Acad Sci U S A. 2018;115(22):5774-9.
  73. Puskas JD, Gerdisch M, Nichols D, Fermin L, Rhenman B, Kapoor D, et al. Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement. J Am Coll Cardiol. 2018;71(24):2717-26.
  74. Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, et al. HIV vaccine candidate activation of hypoxia and the inflammasome in CD14(+) monocytes is associated with a decreased risk of SIVmac251 acquisition. Nat Med. 2018 Jun;24(6):847-856.

Top